🇺🇸 Rifamycine in United States

46 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Necrotising Enterocolitis Neonatal — 8 reports (17.39%)
  2. Drug Reaction With Eosinophilia And Systemic Symptoms — 7 reports (15.22%)
  3. Rash Maculo-Papular — 7 reports (15.22%)
  4. Conjunctivitis — 4 reports (8.7%)
  5. Pyrexia — 4 reports (8.7%)
  6. Toxic Skin Eruption — 4 reports (8.7%)
  7. Drug Rash With Eosinophilia And Systemic Symptoms — 3 reports (6.52%)
  8. Hypotonia — 3 reports (6.52%)
  9. Mydriasis — 3 reports (6.52%)
  10. Pruritus — 3 reports (6.52%)

Source database →

Rifamycine in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Other approved in United States

Frequently asked questions

Is Rifamycine approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Rifamycine in United States?

Yuzuncu Yil University is the originator. The local marketing authorisation holder may differ — check the official source linked above.